There is a steady increase in the number of neuroendocrine tumors. Although the knowledge about this tumors' biology is increasing, they are still diagnosed in advanced stadium, when surgical treatment is not an option. One of the treatment methods which are available in this group of patients is peptide receptor radionuclide therapy, which should be considered in selected patients. This treatment is usually well tolerated by patients, though severe adverse events may occur, such as myelosuppression or renal failure.
Keywords: treatment; metastatic disease; neuroendocrine neoplasms; peptide receptor radionuclide therapy.